Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea
| Autor: | Concepción Boqué, Pilar Aragües, Ana Kerguelen, Valentín García-Gutiérrez, Jose Angel Hernandez-Rivas, Yasmina Cruz, Maria Laura Fox, Beatriz Cuevas, Joaquin Martinez-Lopez, Abelardo Bárez, Elena Magro, Mari Carmen García, Carmen Burgaleta, María Isabel Mata, Juan Luis Steegmann, Francisca Ferrer-Marín, María Teresa Gómez-Casares, Carlos Besses, María Antonia Durán, Clara Martínez, Francesc García, Sara Montesdeoca, Manuel Pérez-Encinas, José María Raya, Juan Carlos Hernández-Boluda, Montse Gómez, Manuel Albors, María-José Ramírez, Alberto Alvarez-Larrán |
|---|---|
| Přispěvatelé: | Instituto de Salud Carlos III, Novartis Farmaceutica |
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
Male
Time Factors Drug Resistance Drug resistance Hematocrit Gastroenterology 0302 clinical medicine Polycythemia vera Phlebotomy hemic and lymphatic diseases Hydroxyurea Platelet Trombosi Registries Young adult Polycythemia Vera Aged 80 and over medicine.diagnostic_test Hematology Articles Middle Aged Thrombosis Combined Modality Therapy Phenotype Treatment Outcome 030220 oncology & carcinogenesis Toxicity Female Adult Risk medicine.medical_specialty Adolescent 03 medical and health sciences Young Adult Internal medicine medicine Humans Aged Policitèmia vera business.industry medicine.disease Surgery Blood Cell Count Spain Multivariate Analysis business 030215 immunology |
| Zdroj: | Repisalud Instituto de Salud Carlos III (ISCIII) Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid Consejería de Sanidad de la Comunidad de Madrid HAEMATOLOGICA r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau instname |
| ISSN: | 0390-6078 |
| Popis: | Hematocrit control below 45% is associated with a lower rate of thrombosis in polycythemia vera. In patients receiving hydroxyurea, this target can be achieved with hydroxyurea alone or with the combination of hydroxyurea plus phlebotomies. However, the clinical implications of phlebotomy requirement under hydroxyurea therapy are unknown. The aim of this study was to evaluate the need for additional phlebotomies during the first five years of hydroxyurea therapy in 533 patients with polycythemia vera. Patients requiring 3 or more phlebotomies per year (n=85, 16%) showed a worse hematocrit control than those requiring 2 or less phlebotomies per year (n=448, 84%). There were no significant differences between the two study groups regarding leukocyte and platelet counts. Patients requiring 3 or more phlebotomies per year received significantly higher doses of hydroxyurea than the remaining patients. A significant higher rate of thrombosis was found in patients treated with hydroxyurea plus 3 or more phlebotomies per year compared to hydroxyurea with 0-2 phlebotomies per year (20.5% vs. 5.3% at 3 years; P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|